Table 2.

Effect of endothelium denudation (E−), L-NAME and indomethacin treatment on E_max and pD₂ to noradrenaline in MRA and to phenylephrine in SMA from rats treated with losartan (Los) or ouabain+losartan (Oua+Los) for 5 weeks

	MRA		SMA
	Emax	pD2	Emax	pD2
Control
Los-treated	114±1	6.07±0.02	95±2	5.78±0.09
Oua+Los-treated	114±2	6.00±0.02	76±6+	5.65±0.12
E−
Los-treated	115±2	6.60±0.03*	122±4*	6.15±0.11*
Oua+Los-treated	117±3	6.56±0.10*	117±3*	6.19±0.07*
L-NAME
Los-treated	120±2	6.34±0.05*	126±4*	6.14±0.06*
Oua+Los-treated	131±5*+	6.32±0.05*	120±4*	6.35±0.08*
Indomethacin
Los-treated	110±3	5.90±0.05*	49±9*	5.26±0.12*
Oua+Los-treated	119±3	5.84±0.06*	70±8	5.73±0.13

Values represent means±s.e.m. t-test:

^*P<0.05 vs Control;

⁺P<0.05, Oua+Los-treated vs Los-treated. N=7–8.